Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Opens in a new tab or window Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction autoantibodies, but a wide range of ...

The Tensilon test was discontinued in the U.S. in 2018. It was performed to help diagnose myasthenia gravis (MG), a neuromuscular junction condition characterized by muscle weakness. The test involved ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data expected in 2025. Click for my IMVT update.

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...